Last reviewed · How we verify
Metformin and Saxagliptin
Metformin reduces hepatic glucose production and improves insulin sensitivity, while saxagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.
Metformin reduces hepatic glucose production and improves insulin sensitivity, while saxagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Metformin and Saxagliptin |
|---|---|
| Sponsor | ikfe-CRO GmbH |
| Drug class | Biguanide + DPP-4 inhibitor combination |
| Target | Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a fixed-dose combination of two oral antidiabetic agents with complementary mechanisms. Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral glucose uptake. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of incretin hormones (GLP-1 and GIP), thereby stimulating glucose-dependent insulin secretion and suppressing glucagon secretion.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
- Headache
- Hypoglycemia
- Upper respiratory tract infection
- Lactic acidosis (rare, metformin-related)
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) (NA)
- Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers (PHASE2, PHASE3)
- Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control (PHASE3)
- Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)
- Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin and Saxagliptin CI brief — competitive landscape report
- Metformin and Saxagliptin updates RSS · CI watch RSS
- ikfe-CRO GmbH portfolio CI